Novo Nordisk

2024 - 8 - 7

Novo Nordisk: En vild rejse fra vægttab til hjerteproblemer!

Novo -- novo aktie -- novo nordisk stock -- novo stock hjertesvigt - medicinalindustri - Novo Nordisk - Ozempic - USA - vægttabsmedicin - Wegovy - Novo - novo aktie - novo nordisk stock - novo stock

Novo Nordisk kæmper med Wegovy-salg og hjerteproblemer, men der er lys i mørket!

Novo Nordisk, den danske medicinalgigant, er lige blevet ramt af en sjælden savn af salg af sin populære vægttabsmedicin, Wegovy. Efter at have offentliggjort et skuffende kvartalsregnskab, hvor salget af Wegovy ikke levede op til forventningerne, har aktien oplevet et dramatisk fald på over 7%. Dette er en usædvanlig situation for Novo Nordisk, som tidligere har haft stor succes med deres GLP-1-baserede medicin. Kombinationen af stigende konkurrence fra andre vægttabsprodukter samt prispres på markedet ser på nuværende tidspunkt ud til at udfordre virksomhedens salg strategier.

Samtidig har Novo Nordisk trukket sin FDA-ansøgning for brugen af Wegovy til behandling af hjertesvigt tilbage, hvilket har skabt yderligere frustration. Indtil videre venter man på, at Zendos medicin, der også konkurrerer inden for vægttab, vil tage et bid af kagen. Dette har ikke været en let rejse for Novo Nordisk, især ikke når man tager i betragtning, at de også har måttet informere investorerne om forsyningsproblemer, der kan påvirke fremtidige muligheder.

Men ikke alt er tabt for Novo Nordisk! De har faktisk set en fordobling af recepter for Wegovy i USA, efter at næsten alle deres blockbuster-vægttabsprodukter er blevet fjernet fra FDA's knaphedsliste. Dette er et tegn på, at der er en efterspørgsel efter deres produkter, i hvert fald på den amerikanske front, mens det sker på et tidspunkt hvor der er overvejelser om, hvordan Medicare kan dække anti-overvægt medicin.

Afslutningsvis er der interessant information om Novo Nordisk, der viser, at de i første halvdel af 2024 har oplevet en stigning på 25% i indtægterne på konstant valuta. Denne vækst skyldes især deres diabetesmedicin, Ozempic, som har set en imponerende vækst på 32%. Med den vækstrate og det velkendte brand, satser vi på, at Novo Nordisk stadig har mange spændende kapitler at byde på i fremtiden! Men hvad skal vi så konkludere? Mon ikke godt, at de snart vil finde balancen mellem vægttab og hjertesundhed?

Post cover
Image courtesy of "Reuters"

Novo Nordisk posts rare miss on sales of obesity drug Wegovy (Reuters)

Novo Nordisk on Wednesday trimmed its full-year profit outlook after reporting weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, ...

Post cover
Image courtesy of "The Wall Street Journal"

Novo Nordisk's Wegovy Sales Disappoint (The Wall Street Journal)

Novo Nordisk shares tumbled more than 7% Wednesday after its blockbuster weight-loss drug Wegovy missed sales expectations as a result of the pharmaceutical ...

Updated: Novo Nordisk yanks Wegovy filing for heart failure from ... (Endpoints News)

Novo Nordisk is running into a speed bump with Wegovy's label expansion efforts in heart disease as it has pulled its FDA submission in heart …

Post cover
Image courtesy of "Investor's Business Daily"

Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On ... (Investor's Business Daily)

Novo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.

Novo Nordisk doubles US Wegovy prescriptions as shortages start ... (Endpoints News)

Nearly all of Novo Nordisk's blockbuster GLP-1 Wegovy and Ozempic drugs have been taken off the FDA shortage list as the company reports a doubling …

Post cover
Image courtesy of "FierceBiotech"

Novo Nordisk axes once-monthly GLP-1/GIP agonist MASH prospect (FierceBiotech)

Novo Nordisk has ended development of a drug candidate that it singled out as an exciting part of its pipeline earlier this year.

Post cover
Image courtesy of "Fortune"

How Denmark got homegrown giant Novo Nordisk to lower Ozempic ... (Fortune)

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Post cover
Image courtesy of "FiercePharma"

Novo Nordisk pulls Wegovy HF submission, will resubmit in 2025 (FiercePharma)

Novo Nordisk's attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold.

Post cover
Image courtesy of "STAT"

Supply issues weigh on Novo Nordisk as drugmaker stumbles with ... (STAT)

LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming obesity medicine field sent Novo Nordisk's ...

Post cover
Image courtesy of "pharmaceutical-technology.com"

Novo Nordisk's Wegovy sales weaken as Eli Lilly's Zepbound exerts ... (pharmaceutical-technology.com)

Shares in Novo Nordisk slid as supply bottlenecks and a more crowded weight loss treatment space depress Wegovy sales.

Post cover
Image courtesy of "STAT"

Novo Nordisk pulls filings for Wegovy in heart failure as it waits for ... (STAT)

Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug Wegovy for a common type of heart failure, saying that waiting for ...

Post cover
Image courtesy of "Motley Fool"

Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript (Motley Fool)

NVO earnings call for the period ending June 30, 2024. Logo of jester cap with thought bubble. Image source: The Motley Fool. Novo Nordisk (NVO - ...

Post cover
Image courtesy of "Morningstar.com"

Novo Nordisk Earnings: Wegovy Supply, Obesity Pipeline in Focus (Morningstar.com)

In the first half of 2024, Novo Nordisk's revenue grew 25% at constant currencies, with 32% GLP-1 diabetes growth (largely Ozempic) and 37% GLP-1 obesity growth ...

Post cover
Image courtesy of "FiercePharma"

Novo re-ups supplies on most doses of obesity med Wegovy (FiercePharma)

With supplies of its star obesity med Wegovy now largely unfettered, Novo Nordisk is dialing up its sales expectations for the remainder of the year—and ...

Post cover
Image courtesy of "The Guardian"

Novo Nordisk cuts profit outlook after weaker sales of weight-loss ... (The Guardian)

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly.

Post cover
Image courtesy of "pharmaphorum"

Wegovy slowdown rattles Novo Nordisk investors (pharmaphorum)

Weaker sales of obesity drug Wegovy cause a dip in Novo Nordisk's share price, but CEO says volume growth is strong and will accelerate in second half.

Explore the last week